

**Reference Number:** FOI2021/531  
**From:** Private Individual  
**Date:** 31 March 2022  
**Subject:** Treatments for Immune Thrombocytopenia

Q1 How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:

- a. Revolade (eltrombopag)
- b. Nplate (romiplostim)
- c. Doptelet (avatrombopag)
- d. Tavlesse (fostamatinib)

A1 Information not held – we do not use any of the above drugs

Q2 In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

A2 Zero. D69.3 Immune thrombocytopenic purpura has not been a primary diagnosis of any patient in the last 6 months.

Although our patients may have the condition as a comorbidity, they would not be referred to a specialist cardiothoracic centre to treat ITP.

Q3 Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

- a. rituximab
- b. mycophenolate mofetil
- c. surgery (splenectomy)

A3 Not applicable, as per A2 above

Q4 Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

A4 No